{"id":3037,"date":"2026-05-23T22:50:24","date_gmt":"2026-05-24T02:50:24","guid":{"rendered":"https:\/\/haidut.me\/?p=3037"},"modified":"2026-05-24T03:07:40","modified_gmt":"2026-05-24T07:07:40","slug":"medicine-serotonin-ssri-can-help-ocd-issues-study-acetylcholine-promotes-serotonin-both-can-cause-ocd","status":"publish","type":"post","link":"https:\/\/haidut.me\/?p=3037","title":{"rendered":"MEDICINE: Serotonin\/SSRI can help OCD issues; STUDY: Acetylcholine promotes serotonin, both can cause OCD"},"content":{"rendered":"

For decades, mainstream medicine has portrayed\u00a0acetylcholine<\/strong>\u00a0as the “learning neurotransmitter” and\u00a0serotonin<\/strong> as the “happy hormone.” Drugs that raise acetylcholine (Alzheimer’s treatments like Aricept) and drugs that raise serotonin (SSRIs for depression and OCD) have been prescribed to millions, despite marginal efficacy and significant side effects. Ray has written extensively about the dark side of both molecules: acetylcholine is a stress signal linked to estrogen dominance and neurological dysfunction, while serotonin is a pro-fibrotic, anti-metabolic agent.<\/p>\n

The study below, published in\u00a0Nature Communications<\/em>, now reveals that\u00a0acetylcholine directly controls serotonin release<\/strong>\u00a0in the dorsal striatum \u2014 meaning raising acetylcholine inevitably raises serotonin, compounding the damage. The researchers identified specialized cells called\u00a0cholinergic interneurons (CINs)<\/strong>\u00a0that act like “conductors” in an orchestra, and they found that this coupling is\u00a0region-specific<\/strong>\u00a0(present in dorsal striatum but not ventral striatum). In OCD models, this system runs in “overdrive,” and the\u00a0nAChR-dependent component<\/strong>\u00a0of serotonin release is selectively amplified.<\/p>\n

As the study below demonstrates, researchers from Hebrew University and Stony Brook University used optogenetics to show that\u00a0acetylcholine can directly trigger serotonin release<\/strong>\u00a0in the dorsal striatum.\u00a0Cholinergic interneurons (CINs)<\/strong>\u00a0\u2014 which were already known to control dopamine \u2014 can also directly trigger serotonin release via\u00a0nicotinic acetylcholine receptors (nAChRs)<\/strong>\u00a0on serotonergic axons. In pre-clinical models of OCD (Sapap3-\/- mice),\u00a0acetylcholine levels are hyperactive<\/strong>, driving a massive surge of serotonin release. The study also found that this acetylcholine\u2013serotonin coupling is\u00a0not detectable in the ventral striatum<\/strong>, despite its denser serotonergic innervation \u2014 meaning the brain has region-specific wiring that allows one system to “take the wheel” only in certain areas.<\/p>\n

This finding completely upends the mainstream narrative. Consider the implications:<\/p>\n

    \n
  1. \n

    Alzheimer’s disease:<\/strong>\u00a0The standard of care has been acetylcholinesterase inhibitors (Aricept, etc.) that raise acetylcholine. These drugs have universally failed to cure or even meaningfully ameliorate Alzheimer’s. Now we know why: raising acetylcholine triggers serotonin release, and high serotonin is known to negatively impact brain health (inflammation, fibrosis, mitochondrial dysfunction). The failure of these drugs is not mysterious \u2014 they were targeting the wrong direction.<\/p>\n<\/li>\n

  2. \n

    OCD:<\/strong>\u00a0Mainstream medicine treats OCD with SSRIs \u2014 drugs that raise serotonin. Yet this study shows that in OCD models,\u00a0acetylcholine is already elevated, driving excessive serotonin release<\/strong>. As the researchers note in the Q&A section: “It’s like blaming a loud orchestra on the violins (serotonin) when the conductor (acetylcholine) is actually the one waving the baton too fast.” SSRIs are “managing the symptoms” of the chemical surge, but the true source is the overactive acetylcholine system. This explains why SSRIs benefit only a fraction of OCD patients and cure even fewer. The truth is exactly backwards: OCD is a state of\u00a0excess acetylcholine and excess serotonin<\/strong>, and the treatment should aim to\u00a0lower<\/strong>\u00a0both, not raise them.<\/p>\n<\/li>\n

  3. \n

    The acetylcholine-serotonin axis:<\/strong>\u00a0I have written previously about the direct link between\u00a0acetylcholine and estrogen signaling<\/strong>. Estrogen upregulates cholinergic activity, which then drives serotonin release. This is why women with estrogen dominance often present with anxiety, OCD-like symptoms, and depression \u2014 all of which are then “treated” with SSRIs that make the underlying problem worse.<\/p>\n<\/li>\n<\/ol>\n

    The study did not provide animal doses or human-equivalent doses, as it was a mechanistic optogenetic study. However, the therapeutic implications are clear:\u00a0blocking the acetylcholine\u2192serotonin interaction<\/strong>\u00a0(via anticholinergic agents or nicotinic receptor antagonists) is a more logical approach than raising serotonin with SSRIs or raising acetylcholine with Alzheimer’s drugs. The researchers explicitly state that “this research opens the door for a new generation of treatments that target the ‘conductor’ cells instead.”<\/p>\n

    https:\/\/www.nature.com\/articles\/s41467-026-70359-6<\/a><\/p>\n

    Acetylcholine Seizes Control of Serotonin Signaling<\/a><\/p><\/blockquote>\n